Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.38 |
| ▸ | KRAS | P01116 | 5/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | BLK | P51451 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24518644 | 0.77 | TDP1 (0.36) | FGFR1FGFR2JAK3EGFRERBB2 | |
| SCHEMBL24037593 | 0.76 | KMT2A (0.36) | FGFR1FGFR2KRASJAK3EGFR | |
| SCHEMBL23328992 | 0.76 | JAK3 (0.37) | FGFR1FGFR2JAK3EGFRERBB2 | |
| SCHEMBL19889001 | 0.73 | FGFR1 (0.41) | FGFR1FGFR2JAK3EGFRERBB2 | |
| SCHEMBL23537915 | 0.73 | CHRM1 (0.38) | KRASJAK3EGFRERBB2BLK | |
| SCHEMBL31281268 | 0.70 | JAK3 (0.44) | FGFR1FGFR2KRASJAK3EGFR | |
| Hydrochloric Acid SCHEMBL8022762 | 0.68 | TEAD3 (0.40) | — | |
| SCHEMBL28661395 | 0.67 | KRAS (0.38) | KRASJAK3 | |
| SCHEMBL16385496 | 0.67 | KRAS (0.42) | KRASJAK3 | |
| SCHEMBL24448631 | 0.67 | JAK3 (0.35) | KRASJAK3EGFRERBB2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | FGFR1 2681/4885FGFR2 2584/4885KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.